St. Francis Cancer Center | St. Francis Cancer Center | Novartis Signature CINC280A2201
st francis cancer center, cancer center greenville sc, cancer care greenville sc, aya cancer care, aya cancer care greenville sc
1367
clinical-trial-template-default,single,single-clinical-trial,postid-1367,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-3.7,wpb-js-composer js-comp-ver-4.12,vc_responsive

Clinical Trials

Novartis Signature CINC280A2201

A Phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Read more>

« Available Clinical Trials